Biotechnology Assets SA

As of December 31, 2025, Biotechnology Assets SA carries a market capitalization of 14.25M, placing it among publicly traded companies globally. Its enterprise value stands at 17.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Biotechnology Assets SA has 72.70M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Biotechnology Assets SA maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Biotechnology Assets SA's stock has declined approximately 48.75% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.22.

As of December 31, 2025, Biotechnology Assets SA holds 594,024.67 in cash and equivalents against 4.01M in total debt, resulting in a net debt position of 3.61M. Total book value stands at 6.96M, with working capital of 1.32M providing operational flexibility.

Biotechnology Assets SA's most recent stock split took place on March 14, 2014.